UA96457C2 - Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением - Google Patents

Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением

Info

Publication number
UA96457C2
UA96457C2 UAA200901892A UAA200901892A UA96457C2 UA 96457 C2 UA96457 C2 UA 96457C2 UA A200901892 A UAA200901892 A UA A200901892A UA A200901892 A UAA200901892 A UA A200901892A UA 96457 C2 UA96457 C2 UA 96457C2
Authority
UA
Ukraine
Prior art keywords
delayed
rheumatoid disease
glucocorticoid treatment
release glucocorticoid
release
Prior art date
Application number
UAA200901892A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ахим Шеффлер
Original Assignee
Нитек Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38739340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA96457(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нитек Фарма Аг filed Critical Нитек Фарма Аг
Publication of UA96457C2 publication Critical patent/UA96457C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение касается способа лечения больного, страдающего от признаков и симптомов, обусловленных ревматическим заболеванием, который предусматривает введение упомянутому больному эффективного количества глюкокортикоида, содержащегося в лекарственной форме с отсроченным высвобождением, которая имеет лаг-фазу продолжительностью приблизительно от 2 ч. до приблизительно 6 ч. с момента введения, причем упомянутое лекарственное средство вводят один раз в сутки вечером в течение по меньшей мере приблизительно двух недель.
UAA200901892A 2006-08-03 2007-08-03 Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением UA96457C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83509306P 2006-08-03 2006-08-03

Publications (1)

Publication Number Publication Date
UA96457C2 true UA96457C2 (ru) 2011-11-10

Family

ID=38739340

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200901892A UA96457C2 (ru) 2006-08-03 2007-08-03 Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением

Country Status (26)

Country Link
US (5) US20080076743A1 (ru)
EP (1) EP2049123B2 (ru)
JP (1) JP2009545546A (ru)
KR (1) KR101430089B1 (ru)
CN (1) CN101466385B (ru)
AU (1) AU2007280636B2 (ru)
BR (1) BRPI0717052A2 (ru)
CA (1) CA2655682A1 (ru)
DK (1) DK2049123T4 (ru)
EA (1) EA015304B1 (ru)
ES (1) ES2400446T5 (ru)
HR (1) HRP20130148T4 (ru)
IL (1) IL195155A (ru)
MA (1) MA30665B1 (ru)
MX (1) MX2009001248A (ru)
MY (1) MY149863A (ru)
NO (1) NO20090958L (ru)
PL (1) PL2049123T5 (ru)
PT (1) PT2049123E (ru)
RS (1) RS52672B2 (ru)
SG (2) SG174026A1 (ru)
SI (2) SI2049123T2 (ru)
TN (1) TNSN08385A1 (ru)
UA (1) UA96457C2 (ru)
WO (1) WO2008015018A1 (ru)
ZA (1) ZA200809858B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
EP2563450B1 (en) * 2010-04-28 2017-07-26 Kimberly-Clark Worldwide, Inc. Device for delivery of rheumatoid arthritis medication
CN103906767A (zh) * 2011-10-10 2014-07-02 米迪缪尼有限公司 对类风湿关节炎的治疗
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) 1958-08-04 1962-08-07 Wander Company Medicinal tablet
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US3125491A (en) 1962-04-06 1964-03-17 Chew able hematinic vitamin tablet
FR1603314A (en) 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2100858B1 (ru) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
DE2445971A1 (de) 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5519057A (en) 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE3930770A1 (de) 1989-09-14 1991-03-28 Wolfgang F Dr Schoener Implantierbare katheter aus medizinisch vertraeglichem elastischen kunststoff
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
HU219341B (en) 1990-07-02 2001-03-28 Roche Diagnostics Gmbh Process for producing pressed, moulded, delayed release dose units and dose units thus produced
JP2521848B2 (ja) 1990-07-02 1996-08-07 ベーリンガー マンハイム ゲーエムベーハー 成形され、圧縮された徐放性単位投薬形態の調製法およびこうして得られた圧縮単位投薬形態
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5310578A (en) 1990-09-17 1994-05-10 Merck Patent Gesellschaft Deposition of cosmetically functional material onto pigments and fillers
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
ES2060465T3 (es) 1991-01-03 1994-11-16 Glaxo Canada Procedimiento para la produccion de preparacion farmaceutica solida.
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
EP0546593B1 (en) 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
WO1993019741A1 (en) 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
GB9215908D0 (en) 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
JPH07507564A (ja) 1992-09-30 1995-08-24 ファイザー・インク. コア及び厚さが一定でないコーティングを含有する物品
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
TW272942B (ru) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5709880A (en) 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
WO1997027843A2 (en) 1996-01-30 1997-08-07 Advanced Polymer Systems, Inc. Targeted delivery of drugs to the lower gastrointestinal tract
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
ATE277739T1 (de) 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
DE69814122T2 (de) 1997-10-09 2004-03-18 Dexcel Pharma Technologies Ltd. Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US20040033267A1 (en) 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
KR20040047747A (ko) 2001-03-13 2004-06-05 펜웨스트 파머슈티칼즈 컴파니 변시치료 제형
AU2002254205B2 (en) 2001-03-15 2007-05-10 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
IN191028B (ru) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
BR0211317A (pt) 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
WO2003011254A1 (en) 2001-07-31 2003-02-13 Capricorn Pharma Inc. Amorphous drug beads
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
MXPA04002973A (es) 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20080145438A1 (en) 2001-12-20 2008-06-19 Beuford Arlie Bogue Micro- and nano-particulate drugs and methods of making thereof
WO2003061626A1 (en) 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
EP1478349A1 (en) 2002-02-21 2004-11-24 Amarin Development AB A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
KR20040091135A (ko) 2002-03-14 2004-10-27 다이이찌 산토리 파마 가부시키가이샤 염산 필지카이니드 함유 정제(건식)
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
EP1542662A1 (en) 2002-09-28 2005-06-22 McNEIL-PPC, INC. Immediate release dosage form comprising shell having openings therein
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
ATE514418T1 (de) 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
SI1631251T1 (sl) * 2003-04-24 2011-10-28 Jagotec Ag Tableta z zakasnjenim sproščanjem in definirano geometrijo jedra
ES2335008T3 (es) 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
WO2005027843A2 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
CA2579732C (en) * 2004-09-10 2014-08-12 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
GB0427455D0 (en) 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
JP2008533157A (ja) 2005-03-14 2008-08-21 マサチューセッツ・インスティテュート・オブ・テクノロジー 疾患および障害の診断および処置のためのナノセル
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
ZA200802602B (en) 2005-08-24 2009-10-28 Rubicon Res Pvt Ltd Controlled release formulation
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
CA2657379A1 (en) 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
US20080014272A1 (en) 2006-07-11 2008-01-17 Phil Skolnick Compositions and Methods for Treatment of Chronic Pain Conditions
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
PT2049123E (pt) 2006-08-03 2013-03-06 Horizon Pharma Ag Tratamento de doença reumatóide com glucocorticóide de libertação retardada
AU2007281433A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EP2063872B2 (en) 2006-08-30 2019-12-04 Jagotec AG Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
CN101563058A (zh) 2006-09-08 2009-10-21 弗米克斯有限公司 有色的或可着色的能起泡的组合物和泡沫
WO2008033351A2 (en) 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations
AU2007320737B2 (en) 2006-11-14 2014-04-03 Celsus Therapeutics Plc Contact lens compositions
WO2008079963A2 (en) 2006-12-22 2008-07-03 Cambrex Charles City, Inc. Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
WO2008094877A2 (en) 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US20100016322A1 (en) 2007-02-28 2010-01-21 Nagesh Nagaraju Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
US8877249B2 (en) 2007-04-13 2014-11-04 Dow Global Technologies Llc Granular material for dosage forms
AU2008240044B2 (en) 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
AU2008288106B2 (en) 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
US20110091566A1 (en) 2007-09-25 2011-04-21 Nirmal Mulye Controlled release pharmaceutical compositions
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
JP2011500553A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 5−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
EP2237795A2 (en) 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
US20110243964A1 (en) 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
JP2011507860A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス, インコーポレイテッド 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
CN101969931A (zh) 2008-03-05 2011-02-09 万能药生物有限公司 包含霉酚酸的调节释放药物组合物及其方法
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2010005687A1 (en) 2008-06-12 2010-01-14 University Of Alabama Huntsville Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases or trauma
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2391369A1 (en) 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage

Also Published As

Publication number Publication date
CN101466385A (zh) 2009-06-24
RS52672B (sr) 2013-06-28
SG10201503411QA (en) 2015-06-29
HK1130423A1 (en) 2009-12-31
US20150141388A1 (en) 2015-05-21
EP2049123A1 (en) 2009-04-22
MA30665B1 (fr) 2009-08-03
ZA200809858B (en) 2009-10-28
SI2049123T2 (sl) 2016-10-28
US20080076743A1 (en) 2008-03-27
MY149863A (en) 2013-10-31
SG174026A1 (en) 2011-09-29
PL2049123T3 (pl) 2013-04-30
IL195155A0 (en) 2009-09-22
PL2049123T5 (pl) 2017-09-29
RS52672B2 (sr) 2018-03-30
MX2009001248A (es) 2009-02-11
AU2007280636A1 (en) 2008-02-07
CN101466385B (zh) 2014-01-08
US20170281648A1 (en) 2017-10-05
TNSN08385A1 (en) 2009-12-29
JP2009545546A (ja) 2009-12-24
DK2049123T3 (da) 2013-03-04
KR101430089B1 (ko) 2014-08-13
US20120070499A1 (en) 2012-03-22
HRP20130148T4 (hr) 2016-10-07
NO20090958L (no) 2009-04-30
ES2400446T3 (es) 2013-04-09
HRP20130148T1 (en) 2013-03-31
US8920838B2 (en) 2014-12-30
BRPI0717052A2 (pt) 2013-10-15
KR20090045149A (ko) 2009-05-07
EP2049123B2 (en) 2016-08-24
WO2008015018A1 (en) 2008-02-07
US20140065214A1 (en) 2014-03-06
US9504699B2 (en) 2016-11-29
SI2049123T1 (sl) 2013-04-30
EA200900259A1 (ru) 2009-06-30
EP2049123B1 (en) 2012-11-28
AU2007280636B2 (en) 2013-07-18
ES2400446T5 (es) 2017-03-13
EA015304B1 (ru) 2011-06-30
PT2049123E (pt) 2013-03-06
DK2049123T4 (en) 2016-11-28
CA2655682A1 (en) 2008-02-07
IL195155A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
IN2012DN06720A (ru)
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
UA103915C2 (ru) Твердая лекарственная форма, которая содержит линаглиптин и ингибитор sglt2, и ее применение
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
IL201479A (en) Use of tapentadol for the preparation of pain medication
WO2011026125A3 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
MY149863A (en) Delayed-release glucocorticoid treatment of rheumatoid disease
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
GB2476418A (en) A medicinal product and treatment
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
EA200970816A1 (ru) Новая лекарственная форма
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
ATE522537T1 (de) (e)-n-ä3-ä1-(8-fluor-11h-10-oxa-1-aza-dibenzo-ä , dü-cyclohepten-5-yliden)-propylü-phenylü- methylsulfon-amid als glucocorticoid- rezeptormodulator zur behandlung rheumatoider arthritis
CY1113915T1 (el) Θεραπεια ρευματοειδους ασθενειας με καθυστερημενης-απελευθερωσης γλυκοκορτικοειδες
RU2008130241A (ru) Способ и средство для реабилитации детей с хроническими риносинуситами
TN2012000256A1 (en) Therapeutic use of protein-polymer conjugates
EA200900603A1 (ru) Применение тимозин альфа-1 для получения лекарственного средства для профилактики и лечения аллергических реакций